BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy

reuters11-14 20:40

** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 8.3% to $3.39 premarket

** Company's experimental immunotherapy to treat early Parkinson's disease was well tolerated with no clinically relevant safety issues, it says citing interim data from a mid-stage study

** Parkinson's disease is a progressive movement disorder of the nervous system, which causes nerve cells in parts of the brain to weaken, become damaged and die

** The therapy, ACI-7104.056, induced high immune response on average 16-fold higher than placebo after 3 immunizations -ACIU

** Company plans to share further data from the study in H1 2025

** Data includes analyses from over 30 patients randomized to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU

** Up to last close, stock down ~37% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483787411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483787411","market":"us","top_or_hot":-1,"title":"BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy</title></head><body><p>** Shares of Switzerland-based drug developer AC Immune <span>ACIU.O</span> rise 8.3% to $3.39 premarket</p><p>** Company's experimental immunotherapy to treat early Parkinson's disease was well tolerated with no clinically relevant safety issues, it says citing interim data from a mid-stage study</p><p>** Parkinson's disease is a progressive movement disorder of the nervous system, which causes nerve cells in parts of the brain to weaken, become damaged and die</p><p>** The therapy, ACI-7104.056, induced high immune response on average 16-fold higher than placebo after 3 immunizations -ACIU</p><p>** Company plans to share further data from the study in H1 2025</p><p>** Data includes analyses from over 30 patients randomized to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU</p><p>** Up to last close, stock down ~37% YTD </p><p> (Reporting by Mariam Sunny in Bengaluru)</p><p> ((Mariam.ESunny@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 20:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4N3ML19S:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 8.3% to $3.39 premarket** Company's experimental immunotherapy...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4N3ML19S:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACIU","symbol_name":"AC Immune SA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4N3ML19S:1","article_id":"2483787411","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483787411","pubTimestamp":1731588059,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 8.3% to $3.39 premarket** Company's experimental immunotherapy to treat early Parkinson's disease was well tolerated with no clinically relevant safety issues, it says citing interim data from a mid-stage study** Parkinson's disease is a progressive movement disorder of the nervous system, which causes nerve cells in parts of the brain to weaken, become damaged and die** The therapy, ACI-7104.056, induced high immune response on average 16-fold higher than placebo after 3 immunizations -ACIU** Company plans to share further data from the study in H1 2025** Data includes analyses from over 30 patients randomized to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU** Up to last close, stock down ~37% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACIU":"AC Immune SA","BK4139":"生物科技"},"translate_title":"BUZZ-AC Immune因帕金森病治疗中期数据而上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACIU":0.9},"content_text":"BUZZ-AC Immune rises on interim mid-stage data for Parkinson's therapy** Shares of Switzerland-based drug developer AC Immune ACIU.O rise 8.3% to $3.39 premarket** Company's experimental immunotherapy to treat early Parkinson's disease was well tolerated with no clinically relevant safety issues, it says citing interim data from a mid-stage study** Parkinson's disease is a progressive movement disorder of the nervous system, which causes nerve cells in parts of the brain to weaken, become damaged and die** The therapy, ACI-7104.056, induced high immune response on average 16-fold higher than placebo after 3 immunizations -ACIU** Company plans to share further data from the study in H1 2025** Data includes analyses from over 30 patients randomized to receive ACI-7104.56 or placebo at a ratio of 3:1 - ACIU** Up to last close, stock down ~37% YTD  (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483787411"}